A share price of United Therapeutics Corp [UTHR] is currently trading at $456.84, up 0.79%. An important factor to consider is whether the stock is rising or falling in short-term value. The UTHR shares have gain 8.98% over the last week, with a monthly amount glided 15.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
United Therapeutics Corp [NASDAQ: UTHR] stock has seen the most recent analyst activity on September 26, 2025, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $569. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on June 02, 2025, and set its price target to $405. On April 25, 2025, downgrade downgraded it’s rating to Equal Weight. BofA Securities upgraded its rating to a Neutral but stick to its price target of $314 on April 21, 2025. Morgan Stanley downgraded its rating to a Equal-Weight and raised its price target to $321 on July 11, 2024. Goldman upgraded its rating to Neutral for this stock on February 12, 2024, and upped its price target to $215. In a note dated February 05, 2024, Leerink Partners initiated an Outperform rating and provided a target price of $330 on this stock.
United Therapeutics Corp experienced fluctuations in its stock price throughout the past year between $266.98 and $455.26. Currently, Wall Street analysts expect the stock to reach $508.67 within the next 12 months. United Therapeutics Corp [NASDAQ: UTHR] shares were valued at $456.84 at the most recent close of the market. An investor can expect a potential return of 11.35% based on the average UTHR price forecast.
Analyzing the UTHR fundamentals
Trailing Twelve Months sales for United Therapeutics Corp [NASDAQ:UTHR] were 3.08B which represents 11.71% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.47%, Pretax Profit Margin comes in at 0.53%, and Net Profit Margin reading is 0.4%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.19 and Total Capital is 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 451.07 points at the first support level, and at 445.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 461.04, and for the 2nd resistance point, it is at 465.25.
Ratios To Look Out For
To put it in perspective, the Current Ratio for United Therapeutics Corp [NASDAQ:UTHR] is 7.26. On the other hand, the Quick Ratio is 6.94, and the Cash Ratio is 3.02. Considering the valuation of this stock, the price to sales ratio is 6.71, the price to book ratio is 2.88 and price to earnings (TTM) ratio is 17.84.
Transactions by insiders
Recent insider trading involved BENKOWITZ MICHAEL, PRESIDENT AND COO, that happened on Oct 06 ’25 when 22500.0 shares were sold. FOUNDER, CHAIRPERSON, AND CHIE, ROTHBLATT MARTINE A completed a deal on Oct 07 ’25 to buy 4000.0 shares. Meanwhile, Chairperson & CEO ROTHBLATT MARTINE A sold 4000.0 shares on Oct 06 ’25.
